Hagino, H. http://orcid.org/0000-0001-8053-1095
Sugimoto, T.
Tanaka, S. http://orcid.org/0000-0001-6817-5235
Sasaki, K.
Sone, T.
Nakamura, T.
Soen, S. http://orcid.org/0000-0002-0955-2747
Mori, S. http://orcid.org/0000-0002-7660-5562
Funding for this research was provided by:
Public Health Research Foundation
Asahi Kasei Pharma Corp.
Article History
Received: 21 February 2021
Accepted: 5 May 2021
First Online: 17 May 2021
Change Date: 27 August 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00198-021-06066-3
Declarations
:
: H Hagino has received lecture fees or grants outside the submitted work from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan Co., Ltd., Mitsubishi Tanabe Pharma Corp., Mochida Pharma Co., Ltd, Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., Taisho Pharmaceutical Co., Ltd., Teijin Pharma Ltd., and UCB Japan Co., Ltd.T Sugimoto has received research grants from Asahi Kasei Pharma Corp., Astellas Pharma Inc., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Pfizer Japan Inc., and Teijin Pharma Co., Ltd., as well as consulting fees from Kissei Pharmaceutical Co., Ltd., Shimadzu Corp., and Takeda Pharmaceutical Co., Ltd.S Tanaka has received lecture fees from Astra-Zeneca, Taiho Pharmaceutical Co., Ltd., and Ono Pharmaceutical Co., Ltd.; consultation fees from DeNA Life Science Inc. and CanBus; and outsourcing fees from Satt Co., Ltd. and Asahi Kasei Pharma Corp.T Sone has received research grants from Astellas Pharma Inc., Eisai Co., Ltd., Daiichi-Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., and Eli Lilly Japan Co., Ltd., as well as consulting and/or lecture fees from Asahi Kasei Pharma Corp., MSD Co., Ltd., and Daiichi-Sankyo Co., Ltd.T Nakamura has received reports personal fees and other from Asahi Pharma Corp., Teijin Pharma Ltd., Daiichi-Sankyo Pharma Co., Ltd., UCB Japan Co., Ltd., Amgen Inc., Astellas Pharma Inc., and Chugai Pharma Co., Ltd. as well as personal fees and other from Merck & Co., Inc.S Soen has received consulting fees, speaking fees, and/or honoraria from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan Co., Ltd., Mochida Pharma Co., Ltd., Ono Pharmaceutical Co., Ltd., Teijin Pharma Ltd., and UCB Japan Co., Ltd.K Sasaki and S Mori declare no competing interests.
: The protocol was approved by the certified review board of Toranomon Hospital and the central ethics committee of the Adequate Treatment of Osteoporosis research group.All procedures performed in this study were in accordance with the Clinical Trials Act of the Japanese Ministry of Health, Labour, and Welfare and with the 1964 Helsinki declaration and its later amendments.
: All patients provided written, informed consent.
: All patients provided written, informed consent.